about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Dai­ichi Sankyo adds $484M pact to its on­go­ing Zymeworks col­lab­o­ra­tion; Sur­face spins out of Im­prim­is with $20M raise

7 years ago
News Briefing

Gilead for­ti­fies its pi­o­neer­ing cell ther­a­py sta­tus, ex­pand­ing in­to three new fa­cil­i­ties and team­ing with NCI

7 years ago
R&D

Third Rock, GV back Broad spin­out Cel­sius in bid to de­vel­op pre­ci­sion meds for au­toim­mune dis­ease

7 years ago
Financing
Startups

Tar­get­ing the tricky PI3K path­way in can­cer, MEI gets $75M to push pro­gram through reg­is­tra­tion study

7 years ago
Financing

CRISPR trail­blaz­ers Zhang, Liu and Joung join forces to launch Beam with $87M and cut­ting-edge gene-edit­ing tech

7 years ago
Financing
Startups

Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain ...

7 years ago
News Briefing

Akari CEO Horn Solomon oust­ed af­ter al­leged­ly abus­ing the com­pa­ny cred­it card

7 years ago
People

Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

8 years ago
News Briefing

Hunt­ing a cure, Ex-No­var­tis ex­ec Bas­tiano San­na takes the reins at Cam­bridge di­a­betes start­up Sem­ma

8 years ago
People

Iron­wood pleas with in­vestors: Don't give us Alex Den­ner

8 years ago
Pharma

Ex-Re­cep­tos CTO co-founds SD start­up Escient, launch­ing with $40M Se­ries A

8 years ago
Financing
Startups

Dai­ichi scores in PhI­II study of AML drug, beat­ing chemo and build­ing its case for world­wide ap­provals

8 years ago
R&D

Genen­tech R&D leader Di­et­mar Berg­er moves to Atara Bio, head­ing up off-the-shelf T cell work

8 years ago
People

Splat: Sin­ga­pore's Aslan tanks on Nas­daq de­but, rais­ing $42M in IPO and trend­ing down

8 years ago
Financing

Re­gen­eron ditch­es high­er dose of pain drug fas­inum­ab in PhI­II, trig­ger­ing safe­ty scare; In a small win for Al­ny­lam, ...

8 years ago
News Briefing

Re­ject­ed: Af­ter pay­ing $80M to ac­quire it, Mallinck­rodt's jaun­dice drug snubbed by FDA's ad­vi­so­ry com­mit­tee

8 years ago
Pharma

Rais­ing a record $668M in new fund, Fore­site sets sights on a tech-dri­ven port­fo­lio

8 years ago
Financing

Third Rock sinks $59M in­to Cas­ma's 're­cy­cling' tech, with neu­ro on the mind

8 years ago
Financing
Startups

High cho­les­terol con­tender Es­pe­ri­on slips on safe­ty con­cerns, stock sinks 30%

8 years ago
R&D

Kym­ri­ah wins sec­ond FDA OK, boost­ing hope for No­var­tis' low CAR-T sales

8 years ago
R&D
Pharma

Roche boosts its gene ther­a­py game, ex­pand­ing part­ner­ship with 4D Mol­e­c­u­lar Ther­a­peu­tics

8 years ago
R&D
Pharma

Karyopharm stock soars on se­linex­or's pos­i­tive PhI­Ib up­date, plans for an NDA

8 years ago
R&D

Eye­ing Eylea's $5B sales, No­var­tis touts sol­id 12-week dos­ing da­ta for its ri­val RTH258

8 years ago
R&D

Spark's PRV draws luke­warm price, sell­ing for $110M to Jazz

8 years ago
Pharma
First page Previous page 45678910 Next page Last page
A service from the Financial Times